Serum IL-33 level and IL-33, IL1RL1 gene polymorphisms in asthma and multiple sclerosis patients

Abstract

BACKGROUND: Asthma is a chronic and complex inflammatory disease of the respiratory tract. Also multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. Against this background, IL-33 and IL1RL1 play a critical part in autoimmune and inflammatory disorders. Here we explored the IL-33 serum level and 2 potential genetic variants in the IL33 gene and its receptor in Iranian asthma and MS patients. METHODS: This study consisted of asthma (n=140) and MS patients (n=140), and healthy subjects (n=72). Genotyping was carried out in 2 genetic polymorphisms, rs1342326 variant of IL-33 and rs10204137 SNP of IL-33 receptor genes, using High Resolution Melt Real Time PCR based method. The level of serum IL-33 also was measured using enzyme-linked immunosorbent assay method. RESULTS: The level of IL33 was significantly higher in asthma and MS patients compared to control group (P< 0.001- P<0.001). The frequency distribution of the genotype in rs1342326 in IL-33 gene in patients with asthma, MS and healthy subjects were not significantly different (P>0.05). The frequency distribution of the genotype in rs10204137 in IL-33 gene in patients MS and healthy subjects were significantly different (p = 0.013) Conclusion: Our findings demonstrated that asthma and MS patients had a higher level of IL-33, which IL-33 receptor genetic polymorphism was associated with MS. Further studies in a larger multicenter setting are needed to explore the value of this marker as a risk stratification biomarker.